Fermented Milk Containing Bifidobacterium lactis DN-173 010 in Childhood Constipation: A Randomized, Double-Blind, Controlled Trial
Tabbers MM et al. – In constipated children, the fermented dairy product containing B lactis strain DN–173 010 did increase stool frequency, but this increase was comparable in the control group. There is currently not sufficient evidence to recommend fermented dairy products containing B lactis strain DN–173 010 in this category of patients.
In this prospective randomized, double-blind, controlled trial, 159 constipated children were randomly allocated to receive either a fermented dairy product that contains B lactis DN-173 010 or a control product twice a day for 3 weeks.
The primary endpoint was the change in stool frequency from baseline to after 3 weeks of product consumption.
Analyses were by intention to treat.
Eleven children did not return to any follow-up visit (5 in the probiotic group, 6 in the control group) and were therefore excluded from the final analysis.
74 children in each group were analyzed.
The change in stool frequency from baseline to after 3 weeks of product consumption increased in both groups, but the difference was not statistically significant.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.